- $1.11bn
- $4.65bn
- $7.61bn
- 47
- 99
- 41
- 66
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 20-F | 20-F | 20-F | 20-F | 6-K |
Standards: | USG | USG | USG | USG | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 3,201 | 3,476 | 5,277 | 7,469 | 7,614 |
Cost of Revenue | |||||
Gross Profit | 718 | 690 | 909 | 1,263 | 1,280 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 2,942 | 3,256 | 5,087 | 7,113 | 7,160 |
Operating Profit | 259 | 220 | 190 | 356 | 453 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | 180 | 134 | 138 | 356 | 409 |
Provision for Income Taxes | |||||
Net Income After Taxes | 138 | 136 | 103 | 283 | 349 |
Minority Interest | |||||
Equity in Affiliates | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 172 | 147 | 95.2 | 240 | 274 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 173 | 148 | 101 | 245 | 274 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 2.84 | 2.49 | 1.2 | 3.43 | 3.8 |